CBD and THCV Combination for Partial Seizure Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for epilepsy, particularly partial seizures, are inadequate due to the lack of effective drugs for varying seizure types and potential side effects, with existing cannabinoid studies showing mixed results and suboptimal dose ranges.
Innovation Solution
The use of cannabidiol (CBD) in daily doses of at least 400mg, preferably between 400 to 800mg, combined with tetrahydrocannabivarin (THCV) in doses of at least 1.5mg, with THCV doses up to 15mg, either as pure cannabinoids or in plant extracts with minimal THC content, to treat partial seizures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antiepileptic drugs are used to treat partial seizures, then seizure control may be achieved, but side effects and treatment failure occur
Solution Approach 1:
The patent extracts and utilizes specific cannabinoids (CBD and THCV) from the cannabis plant to treat epilepsy, separating the therapeutic components from the harmful elements. This extraction approach allows selective use of anti-convulsant compounds while avoiding pro-convulsant or harmful constituents of cannabis.
Solution Approach 2:
The patent applies parameter changes by optimizing the dosage ratios of CBD and THCV, and by controlling THC content to minimal levels. This parameter optimization transforms cannabis from a potentially harmful substance into a therapeutic treatment, achieving seizure control while minimizing side effects.
2Reliability
If cannabis is used to treat epilepsy, then anti-convulsant effects may be achieved, but pro-convulsant effects and treatment inconsistency occur
Solution Approach 1:
The patent segments the complex cannabis plant into specific active compounds (CBD and THCV), allowing targeted treatment for different seizure types. This segmentation enables the formulation to be adapted for partial seizures, generalized seizures, or mixed seizure disorders by adjusting the cannabinoid ratio.
Solution Approach 2:
The patent creates a composite pharmaceutical formulation combining CBD and THCV in specific ratios, with controlled THC content. This composite approach leverages the synergistic anti-convulsant effects of multiple cannabinoids while maintaining treatment consistency across different epilepsy syndromes.
3Reliability
If high doses of cannabinoids are used to achieve therapeutic effect, then anti-epileptic activity increases, but adverse effects and mortality increase
Solution Approach 1:
The patent applies parameter changes by establishing optimal dosage ranges for CBD (400-800mg daily) and THCV (1.5-15mg daily), and by limiting THC content to minimal levels. These parameter optimizations achieve therapeutic anti-epileptic effects while minimizing adverse effects and mortality risks observed in previous studies.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD.